This potential outcome could negatively impact efficacy (via elimination of transduced cells) and represents a safety concern that was recently highlighted when severe adverse events due to immune-mediated cardiac and skeletal muscle inflammation occurred in several Duchenne muscular dystrophy patients with large N-terminal dystrophin deletions participating in AAV-microdystrophin clinical trials (5). The gene discussed is DMD; the disease is Duchenne muscular dystrophy.